A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors

PURPOSE: Maximum tolerated dose, safety, pharmacokinetics, and pharmacodynamics were assessed in this phase 1 study of PNT2258, a BCL-2-targeted liposomal formulation of a 24-base DNA oligonucleotide called PNT100. METHODS: Patients with malignant solid tumors were assigned sequentially to one of te...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tolcher, Anthony W., Rodrigueza, Wendi V., Rasco, Drew W., Patnaik, Amita, Papadopoulos, Kyriakos P., Amaya, Alex, Moore, Timothy D., Gaylor, Shari K., Bisgaier, Charles L., Sooch, Mina P., Woolliscroft, Michael J., Messmann, Richard A.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2013
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3909249/
https://ncbi.nlm.nih.gov/pubmed/24297683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2361-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados